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The immunological surveillance of tumors relies on a speciﬁc recognition of cancer cells and their associate antigens by leucocytes
of innate and adaptive immune responses. However, a dysregulated cytokine release can lead to, or be associated with, a failure
in cell-cell recognition, thus, allowing cancer cells to evade the killing system. The phosphatidylinositol 3-kinase (PI3K) pathway
regulates multiple cellular processes which underlie immune responses against pathogens or malignant cells. Conversely, there is
accumulating evidence that the PI3K pathway is involved in the development of several malignant traits of cancer cells as well as
their escape from immunity. Herein, we review the counteracting roles of PI3K not only in antitumor immune response but also
in the mechanisms that cancer cells use to avoid leukocyte attack. In addition, we discuss, from antitumor immunological point of
view, the potential beneﬁts and disadvantages arising from use of anticancer pharmacological agents targeting the PI3K pathway.
1. PI3K PathwayinTumor Development
and Progression
ThePI3Ksignalingpathwayregulatestheactivitiesofabroad
range of downstream molecular eﬀectors, which in turn act
synergistically to mediate a number of cell behaviors and
properties in both normal and pathological conditions. An
overview of the involvement of PI3K in these conditions
is summarized in Figure 1. Three classes of PI3K enzymes
have been deﬁned. The class I is the most intensely studied
and includes p110α, β, γ,a n dδ catalytic isoforms, which
are controlled by coupling with their proper regulatory
isoforms (p85 and p101) to eﬀect their lipid kinase activity
[1]. The PI3K activation in terms of signaling response
varies according to the type of stimulus. For example, p110α
and δ are recruited and activated at the plasma membrane
upon activation of tyrosine kinase receptors (TKRs) whereas
p110γ requires engagement of G-protein-coupled receptors
(GPCR). Conversely, p110β can be activated by both TKRs
and GPCR [2]. Nevertheless, recent data reveal a more com-
plex regulation for p110δ, as this isoform is linked to speciﬁc
GPCRs signaling [3]. Once activated, PI3K enzymes cat-
alyze the phosphorylation in position 3 of the inosi-
tol ring of phosphoinositides, resulting in the generation
of 3-phosphoinositides, mainly the phosphatidylinositol-3-
trisphosphate (PIP3). These lipids act as docking sites for the
recruitment at plasma membrane of protein-bearing pleck-
strin homology (PH) domain such as Akt/PKB, PDK1, BTK,
and PLCγ. Once bound to PIP3 lipids, these proteins turn
activated and signal to a wide array of downstream eﬀectors
that ultimately leads to multiple cellular responses [4–8].
Thissignalingcascadecanbeantagonizedbytheactionofthe
phosphatase and tensin homolog (PTEN), a widely recog-
nized tumor suppressor which dephosphorylates the PIP3
[9].
The oncogenic transformation of cultured cells as well
as the progression of a variety of tumors in vivo has been
reported to be induced by mutations or overexpression of
p110 isoforms. For example, cultured cells undergo trans-
formation when a catalytically hyperactive mutated isoform
of p110α is ectopically expressed whereas p110β, γ,a n d
δ are oncogenic only when overexpressed [10]. Mutations2 Clinical and Developmental Immunology
of p110α disrupting the interaction with the p85 subunit
can also induce oncogenic transformation in the absence
of the receptor activation [11, 12]. The oncogenic role of
p110α has been previously demonstrated in ovarian cancers,
where an increased number of PIK3CA gene copies was
observed. This was correlated with the overexpression of
the p110α subunit that results in an augmented activity
of PI3 kinase [13]. Mutations of the PIK3CA gene were
found with high frequency in colon, brain, breast, liver, and
gastric cancers suggesting an involvement of isoform p110α
in cancer [14, 15]. The activity of p110β, but not p110α,
was shown to be essential in promoting PTEN-driven
tumorigenesis in an animal model of prostate tumor. Impor-
tantly, Akt is shown to be a mediator of p110β-dependent
tumorigenesis [16]. This ﬁnding was supported by a com-
plementary approach based on the transgenic expression of
a constitutively activated p110β in prostate of mice. In this
study, overexpression of this hyperactive isoform drives the
formation of a intraepithelial neoplasia [17]. p110γ has been
recently shown to positively regulate tumor cell proliferation
in HCC and pancreas cancer [18, 19]. In addition, pharma-
cological inhibition of p110γ in medulloblastoma cell lines
ledtoanimpairmentincellproliferationandsensitizedthem
to cisplatin treatment [20]. A role for p110δ in sustaining
neuroblastoma growth has been recently reported. Both
primaryneuroblastomacellsandtissuesdisplayedanoverex-
pression of p110δ and p85α in comparison with the normal
adrenal gland tissue. Moreover, knockdown of both p110α
and δ isoform triggered defective cell growth, whereas only
p110δ knockdown aﬀected cell survival, via lowering the
expression of the Bcl-2 antiapoptotic family proteins [21].
The progression of multiple B-cell malignancies was found
to be dependent on a constitutive activation of p110δ [22].
In particular, increased levels of p110δ were found in blast
cells from patients with acute myeloid leukemia (AML).
In addition, pharmacological targeting of p110δ resulted in
an inhibition of the AML cell proliferation [23]. Finally,
the PI3K signaling pathway was shown to be constitutively
activated in chronic lymphocytic leukemia B cells (CLL).
Moreover, dysregulation of the PI3K signaling pathway
prevents CLL cell survival by inducing apoptosis through
caspase-3 activation [24].
2. Role of PI3K Pathway inImmuneResponse
to Tumors
Diﬀerent cell types are involved in immune response to
tumors. Natural killer (NK) cells intervene in a ﬁrst-line
defense against tumor cells. These lymphocytes constantly
comb the cell microenvironment, where they check the
expression level of MHC class I at the membrane of their
targets, which can be reduced as a result of viral infection or
oncogenictransformation.NKcellsarecytotoxicagainstcells
that fail to expose MHC class I on their surface, thanks to
NK-inhibiting receptors for MHC class I that exist on
cell membrane of NK cells [25]. Once activated, these re-
ceptors (belonging to three families named KIRs, ILTs, and
NKG2A/CD94)inhibitforthecytolyticactivityofNKcellsby
PI3K
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Figure 1: Schematic model of the PI3K signaling pathway involved
in the regulation of a broad range of cellular activities in both
immune system and cancer.
binding to HLA class I. Beside inhibitory receptors, NK cells
bear diﬀerent activating receptors which elicit their cytolytic
eﬀect on target cells after binding to a broad range of ligands.
OneofthebeststudiedamongtheactivatingreceptorsofNK
cells is the C-type lectin-like superfamily member NKG2D,
which also occurs in CD8 T cell in humans. This receptor
is a transmembrane glycoprotein which binds some known
ligands (MHC class I chain-related molecules (MIC) MIC-
A, -B, and ULBP) which are little expressed on the surface of
normal cells but can be increased in transformed or virus-
infected cells [26]. The antigen-presenting cells (APCs),
primarily dendritic cells (DCs) and macrophages, can prime
speciﬁc CD4+ and CD8+ T-lymphocyte-mediated responses
to cancer cells, thanks to their ability to recognize tumor-
associated or speciﬁc antigens, and present antigen-derived
peptides in the MHC class II. The generation of tumor
addressed T-cell clones is driven by stimulatory signals
occurring when immunological synapses form between
APCs and T-cells. DCs and macrophages secrete cytokines,
such as IL-12, IL-15, IL-18, necessary for induction of NK
and T-cell immunity. IL-12 leads to diﬀerentiation of CD4+
cellsinTh1subtypewhichiseﬀectiveintumorrejection.Th1
cells help expand the population of CD8+ cytotoxic T lym-
phocytes that can directly destroy tumor cells [27]. NK cells
release IFNγ in response to stimulation by both mature DCs
secreted IL-12 and cell-to-cell contact with DCs [28]. Also,
IL-12 stimulate Th1 and CD8+ to secrete IFNγ [29]w h i c h
in turn promotes a wide array of host responses to tumors
[30], including the activation of CD8+ cells [31] and the
recruitment of NK cells within the tumor [32].
Chronic inﬂammation is thought to underlie the onset
of several cancers. Several reports demonstrate that PI3Ks
activity is essential in regulating chemokine production by
leukocytes as well as directional migration of these cells dur-
ing the inﬂammatory response. For example, studies carried
out in vivo using models for inﬂammation show that p110γClinical and Developmental Immunology 3
is required to allow chemotactic migration of neutrophils,
macrophages, and eﬀector CD8 T cells to inﬂammatory
sites [33, 34]. During lung inﬂammation, recruitment of
eosinophils to the bronchial epithelium, together with the
repulsion of neutrophils exerted by chemokine gradients rely
on the activity status of PI3K signaling in these leukocytes
[35]. Moreover, the release of IL-8, Mip-1α, and Mip-1β by
neutrophils in response to LPS and TNFα require the activity
of p85/p110δ complex [36].
Studies performed in mice using loss of function of
p110 isoforms and their related regulatory subunits demon-
strate a crucial role for PI3K in development of immune
cells involved in tumor clearance. The PI3K/Akt-dependent
mTOR pathway is reported to be essential in GM-CSF-
induced diﬀerentiation of DCs from monocytes [37]. Webb
et al. demonstrate that the functions of p110γ and p110δ
PI3K isoforms are required for T-cell development [38]. In a
study recently published, Kerr and Colucci report the need
for p110δ to achieve NK cell maturity, as well as a coopera-
tion between p110γ and p110δ isoforms in establishing the
repertoire of inhibitory receptors of the Ly49 family in mice
(the homolog family in humans is KIR) [39]. Other authors
have previously shown that the achievement of NK cell
subsets maturity is impaired in mice either expressing lipid
kinase-inactive p110δ or lacking regulatory p85α/p55α/p50α
subunits. Moreover, inactive p110δ or p85α/p55α/p50α
depletion was shown to result in signiﬁcantly compromised
NKG2D, Ly49D, and NK1.1 receptor-mediated cytokine and
chemokine generation in NK cells, even if the NK-mediated
cytotoxicity against tumor cells was aﬀected only in mice
lacking p85 regulatory subunit [40, 41].
An involvement of the PI3K/Akt pathway has been
reported in the immune recognition of tumor cells. For
example, in NK cells, the NKG2D-associated adapter protein
DAP10 undergoes Tyr phosphorylation in its cytoplasmic
tail following interaction between NKG2D and activating
ligands. This allows DAP10 to anchor to either the p85
subunit of PI3K or to the adaptor Grb2, leading to PKB/AKT
or MAP kinase signaling activation, respectively. These
signaling cascades enable cytolytic activity and chemokine
production by NK cells [42–44]. Furthermore, the small Ras
family GTPase Rap1 is activated downstream of NKG2D
engagement in a PI3K- and CrkL-dependent manner and is
required for NK cell/target cell conjugate formation, NK cell
polarization, and NKG2D-dependent cellular cytotoxicity
[45]. Diﬀerent activating receptors, other than NKG2D, can
lead to NK cytotoxicity against tumor cells using the adapter
DAP12, instead of DAP10, for PI3K pathway stimulation.
DAP12 is tyrosine phosphorylated upon tumor cell ligation
allowing binding of DAP12 to Syk kinase, which in turn
activates the signaling pathway PI3K, Rac1, PAK1, and ERK
leading to the lytic cascade of NK cells [46].
The engagement of NKG2D through coculturing human
NK cells with MICA-bearing tumor cells leads to a PI3K-
dependent increase of IFNγ secretion by NK cells. This is an
additional eﬀect to IFNγ release upon treatment of the same
cells with IFN-α, IL-12, and speciﬁc agonists for TLR3- and
TLR7-activating receptors [47]. These ﬁndings support the
relevant role of the PI3K pathway as a mediator of the adap-
tive immune response against tumors by activated NK cells.
The role of PI3K in the APCs production of IL-12 remains
controversial. A report by Ohtani and coworkers show a
complex cooperation between the PI3K-downstream GSK3
and mTOR pathways in the regulation of IL-12 secretion
as a consequence of TLR activation by LPS on DCs. These
authors show that GSK-3 and mTOR activities promote and
reduce IL-12 production, respectively. However, the overall
eﬀect of LPS on DCs is to reduce IL-12 secretion, since
PI3K activation blocks GSK-3 function while enhancing the
mTOR signaling [48]. Conversely, other studies show an
overall increased IL-12 production by human macrophages
and DCs, upon LPS stimulation which depends on the
activation of p110β isoform of PI3K [49].
The CD28-dependent costimulating signals required for
thefullactivationofTcellsbyAPCsaremediatedpartiallyby
PI3K functions. CD28 undergoes tyrosine phosphorylation
in its cytoplasmic tail upon binding to APCs costimulatory
ligand B7. This binding recruits p85 subunit at the cell
membrane through the interaction between SH2 domains
of p85 and the phospho-tyr docking sites of CD28. As a
consequence, p85 binds to the catalytic subunit p110 that
activatesPKCθ,whichiscapableofpreventingstress-induced
apoptosis of T cells [50].
3.The PI3K/AktPathwayIsInvolvedin
Escapeof Tumors from Immunological
Surveillance,Immune Suppression,and
AcquiredLeukocyte-LikePropertiesby
CancerCells
T h eP I 3 Kp a t h w a yc a nb er e s p o n s i b l e ,t oac e r t a i ne x t e n t ,
for transformed cells escaping immunity. Examples of some
of the immune escape mechanisms by cancer involving
the PI3K signaling pathway is summarized in Figure 2.
A reduced NKG2D expression and function in NK cells
followingchronicexposuretoNKG2Dligandsand/orsoluble
forms of MIC (sMIC) leads to a immune surveillance failure
[51]. This occurs in chronic myeloid leukemia, where the
BCR/ABL fusion oncoprotein is shown to positively regulate
the expression of MICA/B at the translational level via a
PI3K-dependentmechanismintheBCR/ABL+celllineK562
[52]. Cancer cells can also escape immune surveillance by
developing a de novo expression on their surface of some
molecules which are normally present in immune cells, thus
allowing them to be recognized as normal. Melanoma cells
often express MHC II, and this histological condition is asso-
ciated with poor prognosis. Melanoma-inﬁltrating T cells
express the lymphocyte activation gene 3 (LAG-3), which
is a natural ligand for MHC II. Activation of MHC II on
melanoma cells promotes resistance against FAS-mediated
or drug-induced apoptosis via a mechanism based on
MAPK/ErkandPI3K/Aktpathways[53].Nohandcoworkers
supported furthermore the role of PI3K/Akt axis in the
setting of immune escape. An immune-resistant human
papillomavirus type 16 (HPV-16) E7-expressing tumor cell
line was generated by these authors. A hyperactivation of
Akt, after E7-speciﬁc vaccine administration, was found to4 Clinical and Developmental Immunology
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Figure 2: Examples of the major immune escape mechanisms of diﬀerent types of cancers displaying the involvement of the PI3K signaling
pathway. ↑: upregulation; ↓: downregulation; →: activation/secretion;  : inhibition.
be responsible for the increased resistance of these cells to
CD8(+) T-cell-mediated apoptosis [54].
In addition, cancer can overcome immunity through a
metabolic enhancement arising from de novo expression of
pathways that leukocytes use in anticancer processes. Unex-
pectedly, a de novo expression of the NKG2D/DAP10 com-
p l e xh a sb e e nr e p o r t e di nh u m a nc a n c e rc e l l sb o t hin vitro
and in vivo. Notably, in this study, the authors demonstrate
a complementary function between NKG2D/DAP10 and its
MICA ligand, resulting in a self-suﬃciency of cancer cells in
activating of PI3K/Akt-dependent NKG2D downstream sig-
naling. Therefore, the activation of Akt-downstream mTOR/
S6K/4EBP1 signaling axis upon NKG2D/DAP10 stimulation
is shown to promote a sustained cancer progression via an
increased energetic metabolism [55].
Cancer cells can drive immune suppression by multiple
mechanisms, including the secretion of immune-suppressive
cytokines and chemokines, such as TGFβ and IL-10 [56],
or FasL expressing microvesicles (TMV) which induce
lymphocyteapoptosis [57].ThePI3Ksignalingisreportedto
mediate cellular responses upon exposure to these microen-
vironmental factors. The pleiotropic cytokine TGFβ1 in-
creases the expression of IL-10 and MCP-1 in melanoma
cells, through a crosstalk between Smad, PI3K/AKT, and
BRAF-MAPK signaling pathways. IL-10 induces decreased
MICA expression on melanoma cells in an autocrine loop
and blocks the antitumor functions of DCs and NK cells.
MCP-1 recruits monocytes, which in turn secrete TGFβ1,
FGF, and proangiogenic factors (VEGF), and then diﬀer-
entiate into macrophages. The cooperation of these pro-
cesses can boost the progression of melanoma [58, 59].
Cancer cells can also employ a more indirect mechanism
to inhibit immune surveillance by enhancing the immune-
suppressive function of T-regulatory (Treg) cells. TMV
secreted by cancer cells can convert CD4(+)CD25(–) T cells
into CD4(+)CD25(+)FOXP3(+) Treg, while increasing the
expressionbythesecellsofimmune-suppressivefactors,such
as FasL, IL-10, TGF-β1, CTLA-4, granzyme B, and perforin
[60]. In vitro studies demonstrate that the PI3K-mTOR
pathwayisrequiredfortheGranzymeBreleasebyTreg,upon
prolonged stimulation of TCR and CD28, synergically with
IL-2 stimulation [61]. Moreover, Tregs derived from p110δ
defective mice show an impaired suppression function in
vitro and fail to secrete IL-10 [62].
A central role of PI3K in processes involving leukocytes
motility (inﬂammation, adaptive immune responses, tumor
inﬁltration) has been widely documented [63]. For example,
PI3K isoform p110γ and p110δ are both required to mediate
chemotaxis of NK cells induced by CXCL12 and CCL3
during pregnancy. In addition, p110δ is involved in S1P
and CXCL10-mediated chemotaxis and in NK cell tissue
distribution and tumor inﬁltration [3]. Antigen-activated
p110γ-deﬁcient CD4+ lymphocytes exhibit impaired F-actin
polarization and migration into peripheral inﬂammatory
sites in response to stimulation ex vivo with the CCR4 ligand
CCL22 [64]. Using a mechanism PI3K dependent, cancer
cells can also increase their malignancy by “emulating”
some immune cell chemotactic responses. For example, the
chemokine CCL5 (also called RANTES), previously known
asamotilityfactorforsomeleukocytesduringinﬂammation,
can induce migration and metastasis of human cancer cells
thanks to developing a de novo expression of CCL5 receptorClinical and Developmental Immunology 5
Table 1: Main eﬀects of the PI3K and VEGFR inhibitors on immune cells.
PI3K inhibitors p110 isoform VEGFR2/3
inhibitors Eﬀect Ref.
PIK-75 α
Reduced production of TNF-α and IL-6, reduced expression of human
endothelial cell adhesion molecules (E-selectin, ICAM-1, and VCAM-1), and
human monocyte-endothelial cell adhesion.
[79]
AS-605240 γ Reduced numbers of inﬁltrated proinﬂammatory macrophages and T cells. [80, 81]
AS041164 γ Reduced RANTES-induced chemotaxis/recruitment. [82]
CAL-101 δ Apoptosis of CLL cells and decreased production of various inﬂammatory and
antiapoptotic cytokines by activated T cells.
[72]
IC87114 δ
Reduced antigen-induced airway inﬁltration of inﬂammatory cells, secretion
of T(H)2 cytokines in lungs, and inhibition of monocytic integrin activation
during diapedesis.
[83]
SU5416 Reduced IFNγ secretion by CD4+ CD45RO+ T cells. [84]
E7080 Reduced lymphocytes in tumor. [85]
TSU68 Decreased expression of CXCL1 (by cancer cells) and IL-12 and reduced
neutrophil migration into tumor.
[86]
(CCR5) at their surface, which is not present in non-
cancerouscelllines.Tangetal.havedemonstratedthatchon-
drosarcomacellsexpressCCR5andcansenseCCL5resulting
in increased cell migration and metalloproteinases-3 secre-
tion. The PI3K and NF-κB pathways have been shown to
play an essential role in this scenario [65].
4.Pharmacological Inhibitionof
PI3K in Cancer Treatment andAntitumor
Immune-Response
The choice of suitable anticancer pharmacological agents
requires a careful assessment of their side eﬀects on the
immune defense against cancerous cells. Although the role
of a dysregulated PI3K pathway in the development of malig-
nancyiswelldocumented, acancertreatmentfeaturingPI3K
inhibition might be deleterious to the immune response to
tumors. In advanced renal cell cancer (RCC), treatment with
Sorafenib but not Sunitinib can impair antitumor immune
responses, through inhibiting PI3K and ERK phosphoryla-
tion in NK cells, thus, impeding the release by these cells of
cytokines activating adaptive immune responses (i.e., IFNγ),
as well as killing tumor cell targets [66]. However, this is
in contrast with of antitumor immune enhancement eﬀect
reported for Sorafenib in hepatocellular carcinoma (HCC).
This drug has been reported to downregulate the expression
ofmetalloproteinaseADAM9inHCCcells,whichisinvolved
inproteolyticcleavageofMICA,thereby,allowingthisligand
to be displayed on the HCC cell surface for NK recognition
[67]. A study by Ghebeh and coworkers provides evidence of
detrimental eﬀects arising from a combination of inhibition
of the PI3K/AKT pathway and chemotherapy in an in
vivo xenograft mouse model of cancer treatment. Indeed,
the anthracycline doxorubicin has been shown to mediate
nuclear translocation of the T-cell inhibitory molecule, B7-
H1 (PD-L1, CD274), and phosphorylated AKT in breast
cancer cells in a PI3K-dependent manner, restoring immune
surveillance. Interestingly, these authors show an additional
role for B7-H1 in preventing apoptosis in breast cancer
cells, thus, providing a link between immune resistance
and chemoresistance [68]. In CML therapy, in addition to
diminishing the expression of ligands for the activating im-
munoreceptor NKG2D by tumor cells, the BCR/ABL-
inhibitor Dasatinib can impair NK cell reactivity as well as
IFNγ production. Dasatinib treatment was shown to inhibit
the phosphorylation of PI3K and ERK, which are crucial for
NK cell cytolytic activity [69]. The option of using p110
isoform-speciﬁc inhibitors for cancer treatment must be
considered with care, as the function of a single isoform
can be dually involved in promoting both tumor progression
and antitumor immunity. A failure in NK cell-mediated
clearance of cancerous cells has been reported in studies
using p110δ knock-out mice. Although this isoform pro-
motes the progression of leukemia, p110δ depletion results
inadefectiveabilityofNKcellstodegranulateandkillalarge
variety of target cells [70]. Nevertheless, the use of p110δ
inhibitor CAL-101 has recently proven eﬀective in an ex vivo
model of CLL, a disease that shows a high PI3K activity
[71]. CAL-101 induces apoptosis of malignant cells without
aﬀecting normal T cells or NK cells. However, the eﬀect
of CAL-101 on NK or CD8+ and cell-mediated cytolytic
functions of these cells has not yet been explored [72].
This evidence supports the notion that therapeutic beneﬁts
arising from targeting PI3K isoforms could depend on a
balance between the beneﬁt of purging cancer cells and the
disadvantages of immunological impairment.
Evaluation of whether the inhibition of PI3K enzymes
might lead to beneﬁts in cancer therapy should also be based
on the stage of disease when starting treatment. The sus-
tained activation of lymphocytes in chronic inﬂammation,
which underlies the development of several cancers, relies on
PI3K activity in some cases. For example, p110γ isoform has
been shown to drive the onset of colitis-associated tumors,
due to its role in the activation and inﬁltration of myeloid
cells and recruitment of T cells to the colon [73]. An anti-
inﬂammatory therapy based on p110γ inhibition to prevent
the onset of colitis-associated tumors could interfere with6 Clinical and Developmental Immunology
antitumor immunity when an early stage cancer is already
developing,astheNKcellsreactivitydependsstronglyonthe
activity of this isoform [3].
A quest for PI3K inhibitors with a selective action on
malignant cells without aﬀecting immune cells may reveal
compounds that could oﬀer a promising anticancer strategy
while preserving anticancer immunological reactivity. For
example, Honokiol, a plant-derived compound, was shown
to be eﬃcient in downregulating levels of phospho-S6 and
B7-H1intumorcellsviaPI3K/mTORpathway,thus,impair-
ing the immune resistance of glioma, breast, and prostate
cancer cell lines, while having no eﬀect on critical proin-
ﬂammatoryT-cellfunctions.Thisdoesnot occurwithclassic
PI3K/mTOR inhibitors, including LY294002, wortmannin,
AKT inhibitor III, and rapamycin [74]. Conversely, a selec-
tive therapy based on a speciﬁc pharmacologically induced
T-cell PI3K/AKT pathway would prevent the tumor-induced
death/suppression of immune cells potentially engaged in
tumor clearance. Apoptosis induced in vitro on CD8(+)
T-cells by tumor-derived microvesicles expressing FasL has
been successfully inhibited by treating these lymphocytes
with cytokine-based biologic agents, such as IRX-2, which,
like IL-2, IL-7, or IL-15, block the apoptotic machinery
through Akt activation [75].
5. Role of Immunomodulatory Drugs Currently
ImplementedfortheTreatmentofTumorand
Effect of PI3K Inhibitors on Immune Cells
A number of immunomodulatory drugs are currently under
investigation for their anticancer activity. For instance, a
novel strategy for treatment of advanced malignancies sug-
gests the use of bispeciﬁc T-cell-engaging (BiTE) antibodies
which cluster T-cells and cancer cells, and this results in an
enhanced cytotoxic activity toward tumor cells. The recently
developed therapeutic antibody Blinatumomab has a dual
speciﬁcity for CD19 and CD3. Promising responses arose
from the use of Blinatumomab in B-cell non-Hodgkin’s lym-
phoma (NHL) and B-precursor acute lymphocytic leukemia
(ALL) [76]. PF3512676 can activate TLR9 on plasmocy-
toid dendritic cells, thus, leading to increased expression
of class I/II MHC costimulatory molecules and secretion
of cytokines/chemokines that enhance antitumor NK cell
activity. Lenalidomide can improve host immunity against
tumor cells by stimulating LPS-induced IL-10 as well as cos-
timulators of CD8+ T cells. Furthermore, it induces IL-2 and
IFNγ delivery by T cells, resulting in activation of NK cells
[77]. However, a hyperactive PI3K pathway in tumor cells
can counteract the beneﬁcial eﬀects of immunomodulatory
agents used for enhancing antitumor immune responses.
p110δ isoformwasshowntopromoteactivationofCLLcells,
as well as VEGF and FGF expression in response to lenalido-
mide [78]. With regard to VEGF and PI3 kinase down-
stream Signaling, it is worthy to mention that both VEGF
and PI3 kinase inhibitors have an eﬀect on the immune
cells. Inhibitors and the main eﬀects on the immune cells are
summarized in Table 1.
Immunomodulators that enhance immune response
against low immunogenic cancer-speciﬁc antigens during
vaccine-mediated therapies are currently under develop-
ment. One example is the use of multifunctional immun-
omodulator SA-4-1BBL during vaccination against the E7
HPV-associated oncoprotein for treatment of cervical cancer
[87]. Another example is provided by IFNα that possess
advantageousimmunomodulatorypropertiesincludingacti-
vation of DCs. However, the use of this chemokine in cancer
immunotherapy is limited since it can cause autoimmune
disorders [88]. Another strategy is to employ immune-
directed (rather than antitumor) monoclonal antibodies
(mAbs) targeting cytotoxic T-lymphocyte antigen-4 (CTLA-
4), an inhibitory molecule on T cells. Ipilimumab and
tremelimumab, two anti-CTLA-4 mAbs, have shown a better
clinical antitumor response than the traditional tumor-
targeting mAbs [89].
Immunomodulatory oligonucleotides (IMOs) represent
a new class of compounds with anticancer properties. Their
eﬃcacy in inhibiting tumor formation has been demon-
strated alone or in combination with chemotherapeutic
agents both in vitro and in vivo in breast, prostate, and
nonsmall cell lung cancer. TLR9 was recently found to be
expressed in cancer cells apart from that in APCs. The anti-
cancer activity of TLR9 as a receptor for IMOs and mediator
of IMOs has also been described [90–92]. Thalidomide and
its analogs inhibit angiogenesis indirectly by blocking the
action of TNF-α, while activating costimulation in T cell.
These drugs are employed alone or combined with chem-
otherapeuticsinthetreatmentofsomemalignancies,includ-
ing lung cancer and multiple myeloma [93, 94].
6. Concluding Remarks
Tumor growth may be the result of tumor proliferation and
tumor-induced failure of immunity in killing cancer cells
[95]. The PI3K signaling pathway is required in multiple
processes, including not only cancer progression, escape
of cancer cells from immunological surveillance, immune
suppression and acquisition of leukocyte-like properties by
cancer cells but also anticancer immune responses. This
assumption raises concerns about the proper use of PI3K-
targeting inhibitors. On one hand, the pharmacological
inhibition of PI3Ks in cancer would be beneﬁcial because
of the blockage of tumor growth and immune-suppressive
function mediated by PI3K. On the other hand, it could
be hazardous since the PI3K signaling pathway is crucial
in antitumor immunity. Therefore, to minimize deleterious
eﬀects, a therapeutic inhibition of PI3Ks should be selective
as much as possible on targeting of cancer cells without
having inhibitory eﬀect on the immune system.
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